Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,630 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06080113Enrolling by invitation
Focal radioactive seed implant for prostate cancer
This trial is testing a new way to treat prostate cancer by placing a tiny radioactive seed directly into the main tumor. It's for men with early-stage, slow-growing cancer who have just one visible tumor on MRI.
HerlevAges 18–80 - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT05338866Enrolling by invitation
Chemo plus targeted high-dose radiation for low rectal cancer
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
Guangzhou, GuangdongAges 18–80 - NCT05213962Enrolling by invitation
Radiation after nipple-sparing mastectomy with implant
This study tests local and regional radiation treatment after nipple-sparing mastectomy done with an implant. It may help reduce cancer returning in the breast/nearby tissues for people whose cancer hasn’t spread to distant sites.
Goyang-si, Gyeonggi-doAges 20 years+ - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT04361370Enrolling by invitationPhase 2
Olaparib plus pembrolizumab and bevacizumab after ovarian cancer
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
SeoulAges 20 years+ - NCT03393962Enrolling by invitationPhase 1/Phase 2
Antigen-targeted immune cell treatment for high-risk ovarian cancer
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
Shenzhen, GuangdongAges 10–80 - NCT03025477RecruitingPhase 2
Testing two first-treatment options for advanced ovarian cancer
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
DijonAges 18–75 - NCT07802002Recruiting
Dietary supplement to prevent bowel injury during radiation for rectal cancer
This trial tests whether a special dietary supplement can help protect the rectum from radiation damage during chemoradiation for locally advanced rectal cancer. If it works, it may reduce painful bowel symptoms like frequent stools and cramping.
Guangzhou, GuangdongAges 18–75 - NCT07801287RecruitingPhase 2
Combination treatment before and after surgery for intermediate-stage liver cancer
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
TianjinAges 18 years+ - NCT07801274Recruiting
Focused radiation after spine surgery for metastatic tumors
This trial tests a precise type of radiation therapy given after spine surgery to treat cancer that has spread to the spine. The goal is to reduce pressure on the spinal cord and help control the disease with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07802405RecruitingPhase 1
Testing a new drug alone or with ruxolitinib for myelofibrosis
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
Zhengzhou, HenanAges 3 weeks+ - NCT06774131RecruitingPhase 3
Study of UGN-104 for low-grade upper tract urothelial cancer
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Homewood, AlabamaAges 18 years+ - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Jeffersonville, IndianaAges 18 years+ - NCT06303193RecruitingPhase 1/Phase 2
Testing a kinase inhibitor drug for MDS and MDS/MPN in adults and teens
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
Bethesda, MarylandAges 12–120 - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Gilbert, ArizonaAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT07405151RecruitingPhase 1/Phase 2
New drug for advanced esophageal cancer after other treatments
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT06271291Recruiting
Pancreatic Cancer Detection Study for High-Risk People
This study looks for people at high risk for pancreatic cancer, either because of family history, certain genetic mutations, or concerning pancreatic cysts. Researchers want to follow you over time to find cancer early, when it's easier to treat.
Scottsdale, ArizonaAges 18 years+ - NCT06487481RecruitingPhase 1
Radiation before surgery for recurrent adrenal cancer
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
Bethesda, MarylandAges 18–120
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,630 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.